Cargando…
Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients
PURPOSE: To ensure target coverage in the treatment of esophageal cancer, a density override to the region of diaphragm motion can be applied in the optimization process. Here, we evaluate the benefit of this approach during robust optimization for intensity modulated proton therapy (IMPT) planning....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291176/ https://www.ncbi.nlm.nih.gov/pubmed/34289123 http://dx.doi.org/10.1002/mp.15114 |
_version_ | 1784749083584364544 |
---|---|
author | Visser, Sabine Neh, Hendrike Oraboni Ribeiro, Cássia Korevaar, Erik W. Meijers, Arturs Poppe, Björn Sijtsema, Nanna M. Both, Stefan Langendijk, Johannes A. Muijs, Christina T. Knopf, Antje C. |
author_facet | Visser, Sabine Neh, Hendrike Oraboni Ribeiro, Cássia Korevaar, Erik W. Meijers, Arturs Poppe, Björn Sijtsema, Nanna M. Both, Stefan Langendijk, Johannes A. Muijs, Christina T. Knopf, Antje C. |
author_sort | Visser, Sabine |
collection | PubMed |
description | PURPOSE: To ensure target coverage in the treatment of esophageal cancer, a density override to the region of diaphragm motion can be applied in the optimization process. Here, we evaluate the benefit of this approach during robust optimization for intensity modulated proton therapy (IMPT) planning. MATERIALS AND METHODS: For 10 esophageal cancer patients, two robustly optimized IMPT plans were created either using (WDO) or not using (NDO) a diaphragm density override of 1.05 g/cm(3) during plan optimization. The override was applied to the excursion of the diaphragm between exhale and inhale. Initial robustness evaluation was performed for plan acceptance (setup errors of 8 mm, range errors of ±3%), and subsequently, on all weekly repeated 4DCTs (setup errors of 2 mm, range errors of ±3%). Target coverage and hotspots were analyzed on the resulting voxel‐wise minimum (Vw(min)) and voxel‐wise maximum (Vw(max)) dose distributions. RESULTS: The nominal dose distributions were similar for both WDO and NDO plans. However, visual inspection of the Vw(max) of the WDO plans showed hotspots behind the right diaphragm override region. For one patient, target coverage and hotspots improved by applying the diaphragm override. We found no differences in target coverage in the weekly evaluations between the two approaches. CONCLUSION: The diaphragm override approach did not result in a clinical benefit in terms of planning and interfractional robustness. Therefore, we do not see added value in employing this approach as a default option during robust optimization for IMPT planning in esophageal cancer. |
format | Online Article Text |
id | pubmed-9291176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92911762022-07-20 Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients Visser, Sabine Neh, Hendrike Oraboni Ribeiro, Cássia Korevaar, Erik W. Meijers, Arturs Poppe, Björn Sijtsema, Nanna M. Both, Stefan Langendijk, Johannes A. Muijs, Christina T. Knopf, Antje C. Med Phys THERAPEUTIC INTERVENTIONS PURPOSE: To ensure target coverage in the treatment of esophageal cancer, a density override to the region of diaphragm motion can be applied in the optimization process. Here, we evaluate the benefit of this approach during robust optimization for intensity modulated proton therapy (IMPT) planning. MATERIALS AND METHODS: For 10 esophageal cancer patients, two robustly optimized IMPT plans were created either using (WDO) or not using (NDO) a diaphragm density override of 1.05 g/cm(3) during plan optimization. The override was applied to the excursion of the diaphragm between exhale and inhale. Initial robustness evaluation was performed for plan acceptance (setup errors of 8 mm, range errors of ±3%), and subsequently, on all weekly repeated 4DCTs (setup errors of 2 mm, range errors of ±3%). Target coverage and hotspots were analyzed on the resulting voxel‐wise minimum (Vw(min)) and voxel‐wise maximum (Vw(max)) dose distributions. RESULTS: The nominal dose distributions were similar for both WDO and NDO plans. However, visual inspection of the Vw(max) of the WDO plans showed hotspots behind the right diaphragm override region. For one patient, target coverage and hotspots improved by applying the diaphragm override. We found no differences in target coverage in the weekly evaluations between the two approaches. CONCLUSION: The diaphragm override approach did not result in a clinical benefit in terms of planning and interfractional robustness. Therefore, we do not see added value in employing this approach as a default option during robust optimization for IMPT planning in esophageal cancer. John Wiley and Sons Inc. 2021-08-05 2021-10 /pmc/articles/PMC9291176/ /pubmed/34289123 http://dx.doi.org/10.1002/mp.15114 Text en © 2021 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | THERAPEUTIC INTERVENTIONS Visser, Sabine Neh, Hendrike Oraboni Ribeiro, Cássia Korevaar, Erik W. Meijers, Arturs Poppe, Björn Sijtsema, Nanna M. Both, Stefan Langendijk, Johannes A. Muijs, Christina T. Knopf, Antje C. Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients |
title | Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients |
title_full | Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients |
title_fullStr | Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients |
title_full_unstemmed | Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients |
title_short | Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients |
title_sort | assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients |
topic | THERAPEUTIC INTERVENTIONS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291176/ https://www.ncbi.nlm.nih.gov/pubmed/34289123 http://dx.doi.org/10.1002/mp.15114 |
work_keys_str_mv | AT vissersabine assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT nehhendrike assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT oraboniribeirocassia assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT korevaarerikw assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT meijersarturs assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT poppebjorn assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT sijtsemanannam assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT bothstefan assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT langendijkjohannesa assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT muijschristinat assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients AT knopfantjec assessmentofadiaphragmoverridestrategyforrobustlyoptimizedprotontherapyplanningforesophagealcancerpatients |